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ABSTRACT
Objective: The aim of the study is to provide guidance
regarding the meaning and use of the terms “compliance”
and “persistence” as they relate to the study of medication
use.
Methods: A literature review and debate on appropriate ter-
minology and deﬁnitions were carried out.
Results: Medication compliance and medication persistence
are two different constructs. Medication compliance
(synonym: adherence) refers to the degree or extent of con-
formity to the recommendations about day-to-day treatment
by the provider with respect to the timing, dosage, and fre-
quency. It may be deﬁned as “the extent to which a patient
acts in accordance with the prescribed interval, and dose of a
dosing regimen.” Medication persistence refers to the act of
continuing the treatment for the prescribed duration. It may
be deﬁned as “the duration of time from initiation to discon-
tinuation of therapy.” No overarching term combines these
two distinct constructs.
Conclusions: Providing speciﬁc deﬁnitions for compliance
and persistence is important for sound quantitative expres-
sions of patients’ drug dosing histories and their explanatory
power for clinical and economic events. Adoption of these
deﬁnitions by health outcomes researchers will provide a
consistent framework and lexicon for research.
Keywords: adherence, compliance, deﬁnitions, persistence,
terminology.
Introduction
Inadequate medication compliance and persistence are
age-old problems. When taken in varying degrees of
deviation from the prescribed dosing regimen, medica-
tions have situation-speciﬁc alterations in beneﬁt/risk
ratios, either because of reduced beneﬁts, increased
risks, or both. Numerous studies have demonstrated
that inadequate compliance and nonpersistence with
prescribed medication regimens result in increased
morbidity and mortality from a wide variety of ill-
nesses, as well as increased health-care costs [1–5].
Factoring in actual compliance and persistence is
central to an accurate assessment of effectiveness and
cost-effectiveness of therapy [6]. Health outcome and
cost-effectiveness analyses incorporating measures of
medication usage have been hampered by the lack of
uniformity in standards of deﬁnitions and measure-
ments used to describe the concepts of medication
compliance or persistence [7]. Health outcomes
researchers need general and operationally useful deﬁ-
nitions that would help in standardizing the literature,
in building a common platform for comparing and
combining results, and for aiding in the development
of effective and efﬁcient intervention strategies to
enhance medication compliance and persistence.
The International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) Medication Compli-
ance and Persistence Work Group developed deﬁni-
tions for compliance and persistence during 3 years of
international review and discussion. The purpose of
this article is to provide guidance regarding the
meaning of the terms “compliance” and “persistence,”
to deﬁne them as two separate constructs, and to
provide some examples of how to operationalize them
for use in research.
Methods
Terminology
Selection of “compliance” as the primary term and
“adherence” as a synonym was based on similar usage
by indexing services (e.g., MEDLINE, PubMed). We
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found no authoritative support for the assumption that
“adherence” is a less derogatory term or whether it is
preferred by patients. Commenting on the prolifera-
tion of terms representing compliance, Feinstein [8]
described reasons why such synonyms were not supe-
rior terms: “Adherence seems too sticky; Fidelity has
too many connotations; and Maintenance suggests a
repair crew. Although Adherence has its adherents,
Compliance continues to be the most popular term.”
Literature Review of Deﬁnitions
We reviewed English-language reports of compliance,
adherence, or persistence during the period from 1966
to 2005. Investigations have also used disease-speciﬁc
or study-speciﬁc operational deﬁnitions, sometimes
mixing the terms compliance, adherence, and persis-
tence without adequate delineation. Some authors
carefully separate compliance data from persistence
data but use the term adherence to combine the two
sets of results without a rationale or stated metric. The
use of arbitrary categories of good and poor compli-
ance (often set at 80%) usually was unsupported by
research documenting the appropriateness of the cutoff
for a speciﬁc medication class or disease (e.g., lack of
sensitivity testing or link to outcome) [9]. Reports
rarely document that lower compliance might be a
more precise cutoff point (e.g., 50% or 75%).
Most of the suggested deﬁnitions offered no con-
crete guidance to researchers in methodological or
operational approaches. The result has been a series of
general reviews over the past 30 years, revealing the
difﬁculty of presenting a composite view of compli-
ance, other than to say that patients take less medica-
tion than prescribed [10–15]. The development of
electronic monitors to assess compliance improved the
reliability of the data but did little to address the
confusion created by variations in operational deﬁni-
tions [16,17].
Similarly, a review of the persistence literature
revealed that, although different aspects or constructs
have generally been measured under the heading “per-
sistence,” it was not uncommon to have the same
measures referred to by different names (e.g., persis-
tency, continuous adherence, and discontinuation
rates). “Persistence” has been reported in chronic pre-
vention therapies and described as the time of continu-
ous therapy, demarcated by the time from initiation of
therapy to discontinuation of therapy [18–20]. Persis-
tence was found to be operationally deﬁned alterna-
tively as the time between reﬁlls, number of reﬁlls,
renewal of prescription with an allowance for a pre-
speciﬁed gap [21,22], the proportion of patients dis-
pensed a certain number of days’ supply of medication
[23,24], as well as the proportion of patients continu-
ing to reﬁll prescriptions after a speciﬁed time interval.
Some arbitrary measures such as longer duration of
therapy or greater number of patients completing the
therapy, or the proportion of patients receiving some
kind of therapy after commencement of treatment
have also been used to deﬁne persistence [25,26].
Many reports measure persistence but call it compli-
ance and vice versa [27].
Results
The ISPOR Work Group completed 3 years of review
and discussion at ﬁve international conferences, as well
as review and response to drafts on the website. We
propose deﬁnitions for two discrete terms to describe
two aspects of medication-taking behavior (Fig. 1).
Conceptually, compliance and persistence represent
two constructs that are based on one’s belief in the
efﬁcacy of the medication, the severity of their illness,
and their ability to control it with medication. Com-
pliance follows the initial appraisal of the health threat
and behavioral changes to develop the habit of taking
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Figure 1 Deﬁnitions of compliance and persis-
tence.
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medication in accordance with the physician’s pre-
scription (time, quantity, and frequency).
Proposed Deﬁnitions
Medication compliance. Medication compliance
(synonym: adherence) refers to the act of conforming
to the recommendations made by the provider with
respect to timing, dosage, and frequency of medication
taking. Therefore medication compliance may be
deﬁned as “the extent to which a patient acts in accor-
dance with the prescribed interval and dose of a dosing
regimen.” Compliance is measured over a period of
time and reported as a percentage (Fig. 1). This deﬁ-
nition is operationalized in prospective assessments as
dose taking in relation to what was prescribed. Table 1
shows compliance patterns for a patient prescribed a
once-daily medication. Electronic monitoring provides
sufﬁcient details to calculate the number of doses taken
daily as well as whether the doses were taken at appro-
priate intervals (e.g., approximately 12 hours apart
for a twice-daily dosing). Additional details can be
obtained as number of days with extra doses or
without any doses. The deﬁnition is operationalized in
retrospective assessments as the number of doses dis-
pensed in relation to the dispensing period, often called
the “medication possession ratio (MPR)” [28]. Com-
pliance with the prescription is assumed when the
medication is dispensed. Retrospective prescription
claims database analyses lack the details of daily
dosing that are available with prospective electronic
monitoring; however, as these tools are often the only
sources available for assessing compliance, it is sug-
gested that this caveat is noted when describing com-
pliance in these instances.
Medication persistence. Medication compliance refers
to the act of conforming to a recommendation of con-
tinuing treatment for the prescribed length of time.
Therefore, medication persistence may be deﬁned as
“the duration of time from initiation to discontinua-
tion of therapy” (Fig. 1). Continuing to take any
amount of the medication is consistent with the deﬁ-
nition of persistence. This deﬁnition can be opera-
tionalized in both prospective and retrospective assess-
ments by determining the initiation of treatment, or a
point in time during chronic treatment, to a point in
time deﬁned as the end of the observation period.
Persistence analyses must include a prespeciﬁed limit
on the number of days allowed between reﬁlls, consid-
ered the “permissible gap.” Methods for gap deter-
mination should be based on the pharmacologic
properties of the drug and the treatment situation (i.e.,
the maximum allowable period until when patients
could go without a dose and not anticipate reduced or
suboptimal outcomes) [29,30]. By deﬁnition, persis-
tence is reported as a continuous variable in terms of
number of days for which therapy was available. Per-
sistence may also be reported as a dichotomous vari-
able measured at the end of a predeﬁned time period
(e.g., 12 months), considering patients as being “per-
sistent” or “nonpersistent.”
Conclusions
Clinical outcomes of treatment are affected not only by
how well patients take their medications but also by
how long they take their medications. Thus, compli-
ance and persistence should be deﬁned and measured
separately to characterize medication-taking behavior
comprehensively. Addressing both compliance and
persistence provides a richer understanding of
medication-taking behavior. Determining the clinical
sequelae of being fully or partially compliant or per-
sistent is necessary before dichotomous declarations
about “good” or “poor” compliance and persistence
can be made.
The proposed deﬁnitions are focused on promoting
consistency in terminology and methodology to aid in
the conduct, analysis, and interpretation of scientiﬁc
studies of medication compliance. The deﬁnitions
are geared toward future standardization in medical
research to allow for comparisons among reports, and
use of compliance and persistence data for pharmaco-
economic evaluations. They will also assist researchers
in re-evaluating both the earlier literature and its appli-
cation in practice, with a better understanding of the
differences between compliance and persistence mea-
sures. Standardization will facilitate health policy deci-
sions based on consistent evidence. The adoption of
these deﬁnitions will also help standardize the medical
literature.
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